Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, İftihar Köksal et al.|Critical Care|2022Cited by 93
Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID studyMassimiliano Greco, Nicolas De Schryver, Thomas De Corte et al.|Intensive Care Medicine|2022Cited by 88
Co-infection and ICU-acquired infection in COVID-19 ICU patients: a secondary analysis of the UNITE-COVID data setAndrew Conway Morris, Luis Felipe Reyes, Katharina Köhler et al.|Critical Care|2022Cited by 64
Macronutrient intake is different across Europe: Results of a Belgian cohort of critically ill adultsKarolien Dams, Jean‐Charles Preiser, D. Glorieux et al.|Journal of Critical Care|2025Cited by 0